Refocusing cancer R&D for greater impact: Addressing gaps in disparities and access

DOD cancer research programs face 57% funding cut in year-long continuing resolution
Pancreatic, lung, kidney cancer research programs eliminated

The March 15 continuing resolution has gutted the Department of Defense Congressionally Directed Medical Research Program. The program’s funding was cut by 57%, compared to Fiscal Year 2024 levels—from $1.5 billion to $650 million.

Rathmell: We must support our junior colleagues
“Empathy and listening is a key place to start”

Just consider for a minute if this was the first year of running your lab, if you were on the job market as a physician or scientist right now, if you were a resident contemplating a career in cancer research after fellowship, if you were a graduate student or postdoc, if you were an undergraduate or a technician who was looking toward graduate school.

March 28, 2025

Vol.51 No.12

By W. Kimryn Rathmell

Building a nationally integrated cancer research and treatment network

Cancer care is at an inflection point. The traditional boundaries between academic and community oncology are dissolving, requiring a reimagined approach to patient care and clinical research. At City of Hope, we are implementing a national model that integrates breakthrough research with accessible, advanced treatment across diverse geographic regions.

Jeffrey Lee named chief medical executive at MD Anderson

Jeffrey E. Lee was appointed chief medical executive at The University of Texas MD Anderson Cancer Center, effective April 1.

March 28, 2025

Vol.51 No.12

In Brief

Tracy Smith named co-leader of CPC Research Program at MUSC Hollings

Tracy Smith has joined Ashish Deshmukh as a co-leader of the Cancer Prevention and Control Research Program at MUSC Hollings Cancer Center.

March 28, 2025

Vol.51 No.12

Guest Editorial

Caught in the crossfire: The critical threats facing cancer centers, research, and patient care

NCI-designated cancer centers and academic medical institutions (AMCs) are facing unprecedented threats that jeopardize their ability to conduct groundbreaking research, deliver cutting-edge care, and sustain clinical trials essential to patient treatment.

March 21, 2025

Vol.51 No.11

By Shannon McWeeney and Sorena Nadaf-Rahrov

Refocusing cancer R&D for greater impact: Addressing gaps in disparities and access

YOU MAY BE INTERESTED IN

DOD cancer research programs face 57% funding cut in year-long continuing resolution
Pancreatic, lung, kidney cancer research programs eliminated

Rathmell: We must support our junior colleagues
“Empathy and listening is a key place to start”

Building a nationally integrated cancer research and treatment network

Jeffrey Lee named chief medical executive at MD Anderson

Tracy Smith named co-leader of CPC Research Program at MUSC Hollings

Caught in the crossfire: The critical threats facing cancer centers, research, and patient care

Renew today!

Subscriber content

Refocusing cancer R&D for greater impact: Addressing gaps in disparities and access

YOU MAY BE INTERESTED IN

DOD cancer research programs face 57% funding cut in year-long continuing resolutionPancreatic, lung, kidney cancer research programs eliminated

Rathmell: We must support our junior colleagues“Empathy and listening is a key place to start”

Building a nationally integrated cancer research and treatment network

Jeffrey Lee named chief medical executive at MD Anderson

Tracy Smith named co-leader of CPC Research Program at MUSC Hollings

Caught in the crossfire: The critical threats facing cancer centers, research, and patient care

DOD cancer research programs face 57% funding cut in year-long continuing resolution
Pancreatic, lung, kidney cancer research programs eliminated

Rathmell: We must support our junior colleagues
“Empathy and listening is a key place to start”